Brief: Orchard Therapeutics, Fondazione Telethon And Ospedale San Raffaele Announce Exclusive Worldwide License Agreement For Treatment Of MPS-I
28/05/2019 12:47
May 28 (Reuters) - Orchard Therapeutics PLC ORTX.O :
* ORCHARD THERAPEUTICS, FONDAZIONE TELETHON AND OSPEDALE SAN
RAFFAELE ANNOUNCE EXCLUSIVE WORLDWIDE LICENSE AGREEMENT FOR THE
TREATMENT OF MPS-I
* ORCHARD THERAPEUTICS PLC - TERMS OF DEAL INCLUDE AN
UPFRONT
PAYMENT IN CASH AS WELL AS CONTINGENT PAYMENTS
* ORCHARD THERAPEUTICS - DEAL INCLUDES UPFRONT PAYMENT IN
CASH &
CONTINGENT PAYMENTS ON ACHIEVEMENT OF FUTURE DEVELOPMENT,
REGULATORY, SALES MILESTONES
* ORCHARD THERAPEUTICS - TRIAL IS EXPECTED TO ENROLL UP TO
EIGHT
PATIENTS BY FIRST HALF OF 2020, WITH PRELIMINARY FINDINGS AFTER
ONE YEAR OF FOLLOW-UP.
* ORCHARD THERAPEUTICS - TERMS OF DEAL ALSO INCLUDE ROYALTY
PAYMENTS ON NET SALES
Source text for Eikon: ID:nGNX5YBmDX
Further company coverage: ORTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Orchard Therapeutics
See all newsBrief: Orchard Therapeutics Says Court Of Justice Of England & Wales Sanctioned Scheme Of Arrangement Providing For Acquisition Of Co By Kyowa Kirin Co's Unit
Brief: Orchard Therapeutics Receives U.S. FDA Fast Track Designation For OTL-203 In MPS-IH
Brief: Orchard Therapeutics Says U.S. FDA Advised Co It Does Not Intend To Schedule Advisory Committee Meeting
Orchard Therapeutics rises on buyout deal by Japanese drugmaker
Kyowa Kirin to acquire Orchard Therapeutics for $478 mln